Cardio Diagnostics (NASDAQ:CDIO) Issues Quarterly Earnings Results

Cardio Diagnostics (NASDAQ:CDIO) issued its quarterly earnings results on Monday. The company reported ($0.06) EPS for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.07, Zacks reports. The company had revenue of $0.01 million during the quarter, compared to analyst estimates of $0.13 million. Cardio Diagnostics had a negative return on equity of 415.33% and a negative net margin of 34,911.87%.

Cardio Diagnostics Price Performance

CDIO stock traded up $0.01 during trading on Wednesday, hitting $0.43. The company had a trading volume of 21,754 shares, compared to its average volume of 700,483. The company has a fifty day moving average price of $0.53 and a two-hundred day moving average price of $0.99. Cardio Diagnostics has a fifty-two week low of $0.17 and a fifty-two week high of $3.56.

Wall Street Analysts Forecast Growth

Separately, Benchmark boosted their price objective on Cardio Diagnostics from $1.35 to $2.00 and gave the company a “speculative buy” rating in a research report on Thursday, June 6th.

Cardio Diagnostics Company Profile

Cardio Diagnostics Holdings, Inc, an artificial intelligence-powered precision cardiovascular medicine company, develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease.